Ignyta Inc.

11111 Flintkote Ave Ste A , San Diego, CA 92121

Public
Healthcare & Pharmaceuticals - Biotechnology
around $2.5 - 5M
around 20 - 50
(858) 255-5959
(302) 655-5049


Ignyta, Inc. is an oncology biotechnology company. The Company focuses on an integrated therapeutic (Rx) and companion diagnostic (Dx) strategy for treating cancer patients. Its Rx is focused on discovering, in licensing or acquiring, then developing and commercializing molecularly targeted therapies that, sequentially or in combination, are foundational for eradicating residual disease. Its Dx focuses on pairing the product candidates with biomarker-based companion diagnostics that are designed to identify, at the molecular level, the patients likely to benefit from the therapies. Its entrectinib is an orally bioavailable, small molecule tyrosine kinase inhibitor directed to the tropomyosin receptor kinase (Trk) family tyrosine kinase receptors (TrkA, TrkB and TrkC), ROS1 and anaplastic l... (Source: SEC reports)


Competitor - 1/10
Which company is more competitive with Ignyta Inc.?




40 Contacts at this company
Colin Walsh
Principal Scientist
J Lamoureux
Director, Clinical Laboratory Operations ...
Vanessa Esquibel
Associate Director
Steve Shuey
Director, Clinical Operations
Will Mccarthy
Chief Business Officer
Karen Gilmore, CPA
Contract CFO/Controller
June Mendoza
Clinical Trial Manager
Ge (Gina) Wei
Director, Translational Medicine

Jan 4, 2018 17:50:22
SAN DIEGO--(BUSINESS WIRE)--Ignyta, Inc. (Nasdaq: RXDX), a biotechnology company focused on precision medicine in oncology, announced today that Jonathan Lim,  [...]

Jan 4, 2018 17:30:51
SAN DIEGO--(BUSINESS WIRE)--Ignyta, Inc. (Nasdaq: RXDX), a biotechnology company focused on precision medicine in oncology, announced today that Jonathan Lim,  [...]

Dec 29, 2017 19:18:41
SAN DIEGO--(BUSINESS WIRE)--Ignyta, Inc. (Nasdaq: RXDX), a biotechnology company focused on precision medicine in oncology, today announced that the U.S. [...]

Dec 29, 2017 17:30:25
SAN DIEGO--(BUSINESS WIRE)--Ignyta, Inc. (Nasdaq: RXDX), a biotechnology company focused on precision medicine in oncology, today announced that the U.S. [...]

Dec 22, 2017 19:19:50
SAN DIEGO--(BUSINESS WIRE)--Roche (SIX: RO, ROG; OTCQX: RHHBY) and Ignyta, Inc. (NASDAQ: RXDX) today announced they have entered into a definitive merger agreement for [...]

Get Started Today : Sign up in 20 seconds
Search with 20+ criteria.
Export results in seconds.
Bad emails?
No worry, we give two extras for every bad email.